Impact of ten-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in Finnish children--a population-based study

PloS One
Jukka JokinenJ Pekka Nuorti

Abstract

The ten-valent pneumococcal conjugate vaccine (PCV10) was introduced into the Finnish National Vaccination Program (NVP) in September 2010 with a 2+1 schedule (3, 5, 12 months) without catch-up vaccinations. We evaluated the direct and indirect effects of PCV10 on invasive pneumococcal disease (IPD) among children ≤5 years of age during the first three years after NVP introduction. We conducted a population-based, observational follow-up study. The cohort of vaccine-eligible children (all children born June 1, 2010 or later) was followed from 3 months of age until the end of 2013. For the indirect effect, another cohort of older children ineligible for PCV10 vaccination was followed from 2011 through 2013. Both cohorts were compared with season- and age-matched reference cohorts before NVP introduction. National, population-based laboratory surveillance data were used to compare culture-confirmed serotype-specific IPD rates in the vaccine target and reference cohorts by using Poisson regression models. The overall IPD rate among vaccine-eligible children was reduced by 80% (95%CI 72 to 85); the reduction in vaccine-type IPD was 92% (95%CI 86 to 95). However, a non-significant increase in non-vaccine type IPD was observed. Durin...Continue Reading

References

Nov 6, 2002·Australasian Physical & Engineering Sciences in Medicine·W SrikusalanukulP McCullagh
Mar 5, 2004·The Lancet Infectious Diseases·D BogaertP W M Hermans
Dec 22, 2006·Expert Review of Vaccines·Helena KäyhtyHelena Mäkelä
Nov 4, 2008·Scandinavian Journal of Infectious Diseases·Peter KlemetsJ Pekka Nuorti
Dec 2, 2009·The Journal of Infectious Diseases·Tamara PilishviliUNKNOWN Active Bacterial Core Surveillance/Emerging Infections Program Network
Jun 14, 2012·Journal of Clinical Microbiology·Lotta SiiraAnni Virolainen
Dec 25, 2012·Emerging Infectious Diseases·Shamez N LadhaniElizabeth Miller
Apr 15, 2014·The Lancet. Respiratory Medicine·Carla Magda Allan S DominguesUNKNOWN Brazilian Pneumococcal Conjugate Vaccine Effectiveness Study Group
Jul 19, 2014·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Zitta Barrella HarboePalle Valentiner-Branth

❮ Previous
Next ❯

Citations

Jan 26, 2016·Vaccine·Mitra Saadatian-ElahiChristopher B Nelson
Nov 22, 2015·Anales de pediatría : publicación oficial de la Asociación Española de Pediatría (A.E.P.)·D Moreno-PérezUNKNOWN en representación del Comité Asesor de Vacunas de la Asociación Española de Pediatría (CAV-AEP)
Feb 26, 2016·Human Vaccines & Immunotherapeutics·William P Hausdorff, William P Hanage
Feb 26, 2016·Human Vaccines & Immunotherapeutics·Ana Lucia AndradeAna Luiza Bierrenbach
Oct 16, 2015·BMC Infectious Diseases·Myint Tin Tin HtarHeinz-Josef Schmitt
Apr 19, 2015·The Pediatric Infectious Disease Journal·Arto A PalmuTerhi M Kilpi
Jul 28, 2016·Human Vaccines & Immunotherapeutics·Lijoy VargheseBernard Hoet
Apr 15, 2017·Expert Review of Vaccines·Robert CohenCorinne Levy
Dec 14, 2016·The Lancet Infectious Diseases·Anand ManoharanUNKNOWN Alliance for Surveillance of Invasive Pneumococci (ASIP) Study Group
Feb 9, 2018·Human Vaccines & Immunotherapeutics·Lander WillemPhilippe Beutels
Mar 8, 2019·Thorax·Mark van der Linden, Cynthia G Whitney
Oct 12, 2017·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Pontus NauclerBirgitta Henriques-Normark
Aug 8, 2017·Expert Review of Vaccines·Raul IsturizLuis Jodar
Nov 22, 2019·Expert Review of Vaccines·Javier Nieto GuevaraBernard Hoet
Oct 1, 2019·The Pediatric Infectious Disease Journal·Jorge A GomezEduardo Ortega-Barria
Oct 8, 2019·Expert Review of Vaccines·Myint Tin Tin HtarLuis Jodar

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Software Mentioned

FinIP

Related Concepts

Related Feeds

Bacterial Pneumonia

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Bacterial Meningitis (ASM)

Bacterial meningitis continues to be an important cause of mortality and morbidity throughout the world. Here is the latest research.

Bacterial Pneumonia (ASM)

Bacterial pneumonia is a prevalent and costly infection that is a significant cause of morbidity and mortality in patients of all ages. Here is the latest research.

Acute Disseminated Encephalomyelitis

Acute disseminated encephalomyelitis (ADEM) is a rare inflammatory demyelinating disease of the central nervous system. Discover the latest research on acute disseminated encephalomyelitis here.

Bacterial Meningitis

Bacterial meningitis continues to be an important cause of mortality and morbidity throughout the world. Here is the latest research.